Delivery Order SPE2DB22D3401-SPE2DB25FT5LC
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $5,706.96 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count units). The contract is firm fixed price with no set-aside designation and is scheduled for completion by August 11, 2025. AmerisourceBergen's corporate office in Conshohocken, Pennsylvania will serve as the place of performance for this pharmaceutical delivery. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $18,470.50 to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Ondansetron ODT 4 mg tablets (30-count packaging). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of August 28, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a routine...
- The Defense Logistics Agency awarded a delivery order valued at $4,488.23 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count units). The contract is a firm fixed-price delivery order with an ultimate completion date of June 17, 2025, and carries no set-aside designation, indicating it was competitively awarded. Performance will take place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a $19,211.98 delivery order to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count packaging) under a firm fixed price contract. The award was made competitively with no set-aside designation on April 24, 2025, with completion expected by April 25, 2025. Performance will be executed from the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's...
- The Defense Logistics Agency awarded a delivery order valued at $6,642.00 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count units). This competitive award, issued on August 28, 2025, with an ultimate completion date of August 29, 2025, represents a firm fixed-price transaction with no set-aside designation. The pharmaceutical will be delivered to the company's corporate office location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count units) under a firm fixed-price contract valued at $7,389.26. The award was made on July 22, 2025, with an ultimate completion date of July 23, 2025, and represents a non-set-aside competitive award. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location in the same city. This delivery order...
- The Defense Logistics Agency awarded a $1,293.48 firm fixed price delivery order to AmerisourceBergen Drug Corp for Ondansetron ODT 4 mg tablets (30-count) with a completion date of September 19, 2025. This competitively awarded, non-set-aside contract represents a single delivery order against AmerisourceBergen's broader pharmaceutical supply relationship with the federal government. The work will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a $8,321.43 delivery order to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count units) with a completion date of June 26, 2025. This competitive award employs a firm fixed price structure with no set-aside designation. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a major pharmaceutical distributor serving federal...
- The Defense Logistics Agency awarded a $33,081.12 delivery order to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count units) with an ultimate completion date of August 14, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is classified as a child contract under AmerisourceBergen's larger federal contract vehicle. The pharmaceutical products will be delivered to the company's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $8,939.49 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 MG tablets (30-count packages) on July 29, 2025, with completion scheduled for July 30, 2025. This firm fixed-price delivery order was competitively awarded without set-aside restrictions and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a continuation of the company's role as a...
- SPE2DB22D3401Indefinite Delivery Contract
- SPE2DB22D3401-SPE2DB25FT5LCDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $2,646.18 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count units) with an ultimate completion date of August 5, 2025. This contract utilizes firm fixed-price pricing with no set-aside designation, indicating competitive award to this major pharmaceutical distributor. The place of performance is listed as AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. This prime contract vehicle provides comprehensive global pharmaceutical support to military healthcare programs and enables the company to supply a broad range of medications, vaccines, and medical supplies across multiple therapeutic domains. The arrangement reflects AmerisourceBergen's established role as a critical vendor for federal medical procurement, particularly for the Defense Health Agency and other government healthcare systems, and demonstrates the company's ongoing capability to fulfill pharmaceutical needs through the DLA's medical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.6k | 8/4/25 |